These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34103340)

  • 21. IVIg-induced plasmablasts in patients with Guillain-Barré syndrome.
    Brem MD; Jacobs BC; van Rijs W; Fokkink WJR; Tio-Gillen AP; Walgaard C; van Doorn PA; IJspeert H; van der Burg M; Huizinga R
    Ann Clin Transl Neurol; 2019 Jan; 6(1):129-143. PubMed ID: 30656191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcomes of plasma exchange versus intravenous immunoglobulin for the treatment of Guillain-Barré Syndrome: A double-blind, randomized clinical trial.
    Haridy NA; Shehab MM; Khedr EM
    Restor Neurol Neurosci; 2023; 41(5-6):203-217. PubMed ID: 38217554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes of Serum IgG Dimer Levels after Treatment with IVIg in Guillain-Barré Syndrome.
    Svačina MKR; Röth P; Bobylev I; Sprenger A; Zhang G; Sheikh KA; Lehmann HC
    J Neuroimmune Pharmacol; 2019 Dec; 14(4):642-648. PubMed ID: 31515689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical features and real-world outcomes of Guillain-Barré syndrome in the Philippines.
    I Espiritu A; Separa KJNJ; Milla FJC; Adiao KJB; Leochico CFD; Jamora RDG
    Neurol Res; 2021 Dec; 43(12):995-1004. PubMed ID: 34229572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes in Guillain-Barré Syndrome following a second therapeutic cycle - A single-centre retrospective observational study.
    Faustino P; Coutinho M; Brum M; Medeiros L; Ladeira F
    J Neurol Sci; 2022 Oct; 441():120368. PubMed ID: 35932547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome.
    Doets AY; Hughes RA; Brassington R; Hadden RD; Pritchard J
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD008630. PubMed ID: 31981368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynamics and prognostic value of serum neurofilament light chain in Guillain-Barré syndrome.
    van Tilburg SJ; Teunissen CE; Maas CCHM; Thomma RCM; Walgaard C; Heijst H; Huizinga R; van Doorn PA; Jacobs BC
    EBioMedicine; 2024 Apr; 102():105072. PubMed ID: 38518653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous immunoglobulin in very severe childhood Guillain-Barré syndrome.
    Singhi SC; Jayshree M; Singhi P; Banerjee S; Prabhakar S
    Ann Trop Paediatr; 1999 Jun; 19(2):167-74. PubMed ID: 10690257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
    Lancet; 1997 Jan; 349(9047):225-30. PubMed ID: 9014908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome.
    Kuitwaard K; de Gelder J; Tio-Gillen AP; Hop WC; van Gelder T; van Toorenenbergen AW; van Doorn PA; Jacobs BC
    Ann Neurol; 2009 Nov; 66(5):597-603. PubMed ID: 19938102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of eculizumab in Guillain-Barré syndrome: A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial.
    Kuwabara S; Kusunoki S; Kuwahara M; Yamano Y; Nishida Y; Ishida H; Kasuya T; Kupperman E; Lin Q; Frick G; Misawa S
    J Peripher Nerv Syst; 2024 Sep; 29(3):339-349. PubMed ID: 38987228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of complement in Guillain-Barré syndrome: the ICA-GBS study.
    Davidson AI; Halstead SK; Goodfellow JA; Chavada G; Mallik A; Overell J; Lunn MP; McConnachie A; van Doorn P; Willison HJ
    J Peripher Nerv Syst; 2017 Mar; 22(1):4-12. PubMed ID: 27801990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study.
    El-Bayoumi MA; El-Refaey AM; Abdelkader AM; El-Assmy MM; Alwakeel AA; El-Tahan HM
    Crit Care; 2011 Jul; 15(4):R164. PubMed ID: 21745374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical features and prognosis of patients with Guillain-Barré and acute transverse myelitis overlap syndrome.
    Guo F; Zhang YB
    Clin Neurol Neurosurg; 2019 Jun; 181():127-132. PubMed ID: 31039494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Albumin levels as a biomarker for second Intravenous Immunoglobulin (IVIG) treatment in Guillain-Barre syndrome (GBS).
    Shalman A; Savir S; Mechnik Steen Y; Ovanyan A; Boniel N; Koyfman L; Bichovsky Y; Zlotnik A; Klein M; Brotfain E
    J Clin Neurosci; 2020 Apr; 74():247-249. PubMed ID: 32088107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Temporal profile of anti-ganglioside antibodies and their relation to clinical parameters and treatment in Guillain-Barré syndrome.
    Press R; Matá S; Lolli F; Zhu J; Andersson T; Link H
    J Neurol Sci; 2001 Sep; 190(1-2):41-7. PubMed ID: 11574105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The usefulness of chief complaints to predict severity, ventilator dependence, treatment option, and short-term outcome of patients with Guillain-Barré syndrome: a retrospective study.
    Wang Y; Shang P; Xin M; Bai J; Zhou C; Zhang HL
    BMC Neurol; 2017 Nov; 17(1):200. PubMed ID: 29157205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome.
    van Doorn PA; Van den Bergh PYK; Hadden RDM; Avau B; Vankrunkelsven P; Attarian S; Blomkwist-Markens PH; Cornblath DR; Goedee HS; Harbo T; Jacobs BC; Kusunoki S; Lehmann HC; Lewis RA; Lunn MP; Nobile-Orazio E; Querol L; Rajabally YA; Umapathi T; Topaloglu HA; Willison HJ
    J Peripher Nerv Syst; 2023 Dec; 28(4):535-563. PubMed ID: 37814551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Guillain-Barre syndrome and IVIg: does early initiation of treatment influence the mean hospital stay?].
    Coll-Cantí J; Alvarez-Ramo R; Dorado L; Guerrero C; Serichol M; Dávalos A; Martínez EM
    Neurologia; 2009 May; 24(4):217-9. PubMed ID: 19603290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome.
    van Doorn PA; Van den Bergh PYK; Hadden RDM; Avau B; Vankrunkelsven P; Attarian S; Blomkwist-Markens PH; Cornblath DR; Goedee HS; Harbo T; Jacobs BC; Kusunoki S; Lehmann HC; Lewis RA; Lunn MP; Nobile-Orazio E; Querol L; Rajabally YA; Umapathi T; Topaloglu HA; Willison HJ
    Eur J Neurol; 2023 Dec; 30(12):3646-3674. PubMed ID: 37814552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.